Sionna Therapeutics, Inc. Common Stock (SION) Stock
NASDAQ · SION
5.96
Fundamentals
Market cap
$269.47M
Price / Earnings ratio
-3.3x
Price / Sales ratio
N/A
Price / Book ratio
1.2x
Return on assets
-0.3%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
SectorHealthcare
IndustryBiotechnology
Employees59
IPO DateFeb 7, 2025
HeadquartersWaltham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Caroline Stark Beer M.B.A. | Chief Business Officer | 1979 |
| Dr. Greg Hurlbut Ph.D. | Co-Founder & Senior VP of Discovery Research | — |
| Dr. Mark Munson Ph.D. | Co-founder & Senior VP of Medicinal Chemistry | — |
| Mr. Andy Chu | Vice President of Information & Technology | — |
Fundamentals
Valuation
Market cap$269.47M
Price-to-sales ratioN/A
Price-to-book value1.22
Price-earnings ratio-3.30
Return on Equity-27.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.17
Income Statement
Average volume1,437,730
EBITDA$-82.96M
1 year high (52w)$54.97
1 year low (52w)$4.01
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



